Please login to the form below

Not currently logged in
Email:
Password:

licensing agreements

This page shows the latest licensing agreements news and features for those working in and with pharma, biotech and healthcare.

‘Post-Brexit landscape for EU-wide IP Rights: The Story So Far’

‘Post-Brexit landscape for EU-wide IP Rights: The Story So Far’

Licensing. Also of relevance to the pharmaceutical sector is the impact of Brexit on IP licensing. ... Future licence agreements should be drafted to specifically address the effect of Brexit on any relevant provisions.

Latest news

  • GSK unveils access plan for low-income countries GSK unveils access plan for low-income countries

    The MPP was set up in 2010 and focuses on voluntary licensing agreements with companies serving in low-income countries and LMICs. ... month. Another firm active in this area is Gilead Sciences, which signed licensing deals with Indian generics companies

  • AstraZeneca signs $2bn deal to buy Almirall respiratory portfolio AstraZeneca signs $2bn deal to buy Almirall respiratory portfolio

    As well as resisting the $100bn overture from Pfizer earlier this year, Soriot has instigated a range of acquisitions and licence agreements. ... These include licensing the WEE1 inhibitor MK-1775 from Merck &Co, the $500m buyout of biotech Amplimmune

  • AZ buys into ADC sector with $440m Spirogen deal AZ buys into ADC sector with $440m Spirogen deal

    Pushes into the market for antibody-drug conjugates. AstraZeneca has made a push into the market for antibody-drug conjugates (ADCs) via the acquisition of Spirogen and a licensing deal with ... The agreements will allow it to "accelerate ADCs into the

  • Demystifing corporate culture in pharma

    Today, P&G's Connect Develop strategy has resulted in more than 1, 000 active agreements with external parties. ... In addition to trimming product lines, investing in design, terminating licensing agreements and entering into agreements with Microsoft,

  • Lilly partner with Alizé Pharma on diabetes

    The group handles preclinical and clinical development and establishes partnerships with the pharmaceutical industry via codevelopment or out-licensing agreements.

More from news
Approximately 0 fully matching, plus 24 partially matching documents found.

Latest Intelligence

  • Sourcing R&D innovation: why pharma companies need to evolve their business models Sourcing R&D innovation: why pharma companies need to evolve their business models

    Internal teams led the clinical side of R&D, while business development teams worked to identify collaboration opportunities, including partnerships or licence agreements with other companies to build their pipelines. ... They also can help identify

  • The search for effective drug treatments for COVID-19 The search for effective drug treatments for COVID-19

    Beyond this network, in the developing world, we have entered into non-exclusive voluntary licensing agreements with nine generic manufacturers to further expand access and supply of remdesivir. ... These agreements are royalty-free during the pandemic

  • Leo has its eyes on the prize Leo has its eyes on the prize

    We will be very active in building partnerships and licensing agreements.

  • A new route to market A new route to market

    Licensing agreements. A common model for many small to medium sized biotech companies taking a first step in exporting is to license a product or technology to a local market partner - ... Licensing agreements are rarely straightforward, and a level of

  • Pharma deals during October 2013 Pharma deals during October 2013

    Deal Watch: Major pharma collaborations, acquisitions and agreements in the past month. ... Pre-existing out-licensing agreements, which include milestones and royalties, remain in effect and these have been transferred into a holding company 75 per cent

More from intelligence
Approximately 1 fully matching, plus 8 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Jet Off with Maloff Protect

Latest intelligence

What does the future hold for Light-chain Amyloidosis?
Recent advances in the understanding and treatment are reforming pharma’s approach to the management of this rare disease. With a new standard of care rapidly developing, what does the landscape...
Webinar:
Securing a future for telehealth with immersive market research insights...
Accelerating patient recruitment in clinical trials with the Clinical Enrolment Managers (CEMs)
How Innovative Trials' global Clinical Enrolment Managers (CEMs) give clinical trial sites the local touch...